Clinical trials: Bone Diseases
Degenerative Disc Disease
Trinity Elite in Lumbar Fusion
This prospective, post-market, open label clinical study is designed to examine the lumbar fusion rate at 24 months post operative in subjects who have undergone a lumbar fusion surgery using Trinity Elite with or without local…
- Trial name
- NCT02969616
- Testing
- Trinity Elite
- Volunteers
- 300 people
- Sponsor
- Orthofix Inc.
Hematologic Malignancy
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
- Trial name
- NCT02352558
- Testing
- BBI608, Dexamethasone, Bortezomib
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma America, Inc.
Iron Overload
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
The study is designed to collect safety and efficacy of Desferasirox in Chinese patients with Iron Overload and Aplastic Anemia.
- Trial name
- NCT01546415
- Testing
- Desferasirox
- Where
- 7 sites in China
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Acute Lymphocytic Leukemia (ALL)
Expanded Access to Navitoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
- Trial name
- NCT03592576
- Testing
- Navitoclax, Venetoclax
- Sponsor
- AbbVie
Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia.
- Trial name
- NCT07052006
- Testing
- HT-6184
- Where
- 10 sites in India
- Volunteers
- 37 people
- Sponsor
- Halia Therapeutics, Inc.
Growth Hormone Deficiency
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
This will be the first clinical study of the development of PHA-794428 in a pediatric population. Since differences in PK and/or PD response may occur between adult and pediatric subjects, it is deemed appropriate to first…
- Trial name
- NCT00314938
- Testing
- PHA-794428
- Where
- 7 sites in Belgium, France and 3 more
- Volunteers
- 32 people
- Sponsor
- Pfizer
Osteoporosis
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects
- Trial name
- NCT03824171
- Testing
- Raloxifene 60mg/Cholecalciferol 800IU, AD-102
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Myeloid Leukemia, Lymphoblastic Leukemia
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related…
- Conditions
- Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00967343
- Testing
- Donor lymphocyte preparation depleted of host functional alloreactive T-cells
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Kiadis Pharma
Painful Bone Metastases, Breast Carcinoma
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
This study will evaluate treatment with High Intensity Focused Ultrasound (HIFU)in combination with ThermoDox (liposomal doxorubicin) is safe and effective in reducing pain for patients with painful bone metastases.
- Conditions
- Painful Bone Metastases, Breast Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01640847
- Testing
- High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox
- Sponsor
- Imunon
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
- Trial name
- NCT03225287
- Testing
- Zilucoplan (RA101495)
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 19 people
- Sponsor
- Ra Pharmaceuticals, Inc.
Osteoporosis
Bone Effects of Teriparatide Following Alendronate
The purpose of this study is to assess the effect of 24 months of treatment with once daily teriparatide injection (recombinant human PTH [1-34]) 20 micrograms on bone histomorphometry and architecture.
- Trial name
- NCT00191893
- Testing
- teriparatide
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Chronic Phase Chronic Myeloid Leukemia
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.
- Trial name
- NCT01660906
- Testing
- Dasatinib
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Leg Length Inequality
Study to Assess the Pain, Satisfaction, and Quality of Life of Patients With FITBONE® Lengthening Nail
This study is a prospective observational non-interventional multi-centre cohort study of patients, 12 years or older, initiating a lower limb lengthening procedure with FITBONE and who have a length discrepancy of 30mm or more…
- Trial name
- FitForFrance (NCT06156384)
- Testing
- FITBONE® Lengthening Nail
- Where
- 6 sites in France, Reunion
- Volunteers
- 45 people
- Sponsor
- Orthofix s.r.l.
Periodontitis, Alveolar Bone Loss
Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)
This study aims to verify the effectiveness of Trafermin (recombinant human basic fibroblast growth factor) in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the safety of such stimulation.
- Conditions
- Periodontitis, Alveolar Bone Loss, Periodontal Attachment Loss
- Trial name
- NCT00734708
- Testing
- Trafermin (genetical recombination)
- Where
- 21 sites in Japan
- Volunteers
- 328 people
- Sponsor
- Kaken Pharmaceutical
Osteoporosis
Open Label Extension Study of PREOS
This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human…
- Trial name
- OLES (NCT00172133)
- Testing
- ALX1-11 (drug)
- Where
- 132 sites in United States, Argentina and 6 more
- Volunteers
- 1,683 people
- Sponsor
- Shire
Hemoglobinuria, Paroxysmal
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
- Trial name
- NCT00122304
- Testing
- eculizumab
- Where
- 48 sites in United States, Australia and 11 more
- Volunteers
- 85 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Left Ventricular Dysfunction
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.
- Trial name
- NCT00938847
- Testing
- PCI
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Asklepios proresearch
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation